SAR245409
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Indolent Non-Hodgkin Lymphoma
Conditions
Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
Trial Timeline
Dec 1, 2011 → May 1, 2014
NCT ID
NCT01410513About SAR245409
SAR245409 is a phase 1 stage product being developed by Sanofi for Indolent Non-Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01410513. Target conditions include Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.
What happened to similar drugs?
0 of 3 similar drugs in Indolent Non-Hodgkin Lymphoma were approved
Approved (0) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01596270 | Phase 1 | Completed |
| NCT01410513 | Phase 1 | Completed |
| NCT01403636 | Phase 2 | Completed |
Competing Products
15 competing products in Indolent Non-Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ME-401 | Kyowa Kirin | Phase 1 | 29 |
| ME-401 | Kyowa Kirin | Phase 2 | 39 |
| Linperlisib ； Rituximab | Jiangsu Hengrui Medicine | Phase 1/2 | 39 |
| GP2013 | Novartis | Phase 1 | 29 |
| Ibrutinib + GA 101 | Roche | Phase 2 | 31 |
| Obinutuzumab + Bendamustine | Roche | Phase 2 | 35 |
| Placebo + Rituximab + Idelalisib | Gilead Sciences | Phase 3 | 32 |
| Idelalisib | Gilead Sciences | Phase 1/2 | 32 |
| Idelalisib + Rituximab + Bendamustine + Placebo | Gilead Sciences | Phase 3 | 32 |
| Idelalisib + Rituximab + Bendamustine + Ofatumumab + Fludarabine + Everolimus + Bortezomib + Chlorambucil + Lenalidomide | Gilead Sciences | Phase 1 | 29 |
| IBI376 | Innovent Biologics | Phase 2 | 35 |
| Copanlisib + Nivolumab + Rituximab | Bristol Myers Squibb | Phase 1 | 21 |
| Copanlisib (BAY80-6946) | Bayer | Pre-clinical | 23 |
| Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2 | Lundbeck | Phase 3 | 37 |
| Bezuclastinib | Cogent Biosciences | Pre-clinical | 27 |